Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Mitsubishi Tanabe, Daiichi Sankyo Expand Tie-Up to Push DPP-4/SGLT-2 Combo
Mitsubishi Tanabe Pharma and Daiichi Sankyo said on March 29 that they have concluded a marketing alliance pact for MT-2412, Mitsubishi Tanabe’s fixed-dose combination drug containing a dipeptidyl peptidase-4 (DPP-4) inhibitor and sodium-glucose co-transporter-2 (SGLT-2) inhibitor. MT-2412 contains the DPP-4…
To read the full story
Related Article
- Canalia, Japan’s 1st DPP-4/SGLT-2 Combo, Now Available
September 8, 2017
- Canaglu-Tenelia Combo Filed in Japan: Mitsubishi Tanabe
August 23, 2016
- MTPC to Push Tenelia, Canaglu to Compete in Diabetes Field
May 9, 2014
BUSINESS
- Sanofi Eyes Double-Digit Annual Growth for Japan Vaccine Business: Exec
May 20, 2026
- Takeda Hit with Massive Damages Verdict in US Amitiza Antitrust Case
May 20, 2026
- Tapinarof Cream Logs Positive Data in Infant Atopic Dermatitis: Shionogi
May 20, 2026
- Bayer Files FXIa Inhibitor Asundexian in Japan
May 20, 2026
- Japan’s Big 4 Drug Wholesalers See Profit Pressure Intensify in FY2025
May 19, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…